Citation Impact
Citing Papers
A "Silent" Polymorphism in the MDR 1 Gene Changes Substrate Specificity
2006 StandoutScience
Common Variation in the DIO2 Gene Predicts Baseline Psychological Well-Being and Response to Combination Thyroxine Plus Triiodothyronine Therapy in Hypothyroid Patients
2009
Stimulation of colonic motility by oral PEG electrolyte bowel preparation assessed by MRI : comparison of split vs single dose
2014
Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases
2016 Standout
Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report
2012 Standout
T3Augmentation in Major Depressive Disorder: Safety Considerations
2011
Emerging therapies for the treatment of hepatitis C
2013 StandoutNobel
Multidrug Resistance-Associated Proteins: Expression and Function in the Central Nervous System
2006
Depression
2018 Standout
Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II
2010
Polymorphisms in Type 2 Deiodinase Are Not Associated with Well-Being, Neurocognitive Functioning, and Preference for Combined Thyroxine/3,5,3′-Triiodothyronine Therapy
2005
Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer
2015
From traditional Chinese medicine to rational cancer therapy
2007 Standout
Non-invasive quantification of small bowel water content by MRI: a validation study
2007
Drugs as CYP3A Probes, Inducers, and Inhibitors
2007
Calcineurin Inhibitor Nephrotoxicity
2009 Standout
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
2013 Standout
Review article: the role of butyrate on colonic function
2007 Standout
Polymorphism of human cytochrome P450 enzymes and its clinical impact
2009
An Investigation into the In Vivo Performance Variability of pH Responsive Polymers for Ileo-Colonic Drug Delivery Using Gamma Scintigraphy in Humans
2006
Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors
2007
Structure and function of the blood–brain barrier
2009 Standout
Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism
2014
Metabolic Effects of Liothyronine Therapy in Hypothyroidism: A Randomized, Double-Blind, Crossover Trial of Liothyronine Versus Levothyroxine
2011
Partial Substitution of Thyroxine (T4) with Tri-Iodothyronine in Patients on T4Replacement Therapy: Results of a Large Community-Based Randomized Controlled Trial
2005
Glioblastoma and Other Malignant Gliomas
2013 Standout
Fate, activity, and impact of ingested bacteria within the human gut microbiota
2015
Efficacy of Combined Levothyroxine and Liothyronine as Compared with Levothyroxine Monotherapy in Primary Hypothyroidism: A Randomized Controlled Trial
2009
Performance comparison of a co-crystal of carbamazepine with marketed product
2006
Effect ofMDR1C3435T polymorphism on cure rates ofHelicobacter pyloriinfection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation toCYP 2C19 genotypes and 23S rRNA genotypes ofH. pylori
2007
Multigenic control of thyroid hormone functions in the nervous system
2008
Impact of P-glycoprotein on clopidogrel absorption
2006
Molecular Pharmacokinetics of Catharanthus (Vinca) Alkaloids
2007
The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross‐over study in thyroidectomized patients
2010
Clinically relevant drug interactions with antiepileptic drugs
2005
Irritable bowel syndrome
2016 Standout
Air pollution: mechanisms of neuroinflammation and CNS disease
2009 Standout
Potential Role of Drug Transporters in the Pathogenesis of Medically Intractable Epilepsy
2005
Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
2007 Standout
Evaluation of Various Dissolution Media for Predicting In Vivo Performance of Class I and II Drugs
1998 Standout
Targeting multidrug resistance in cancer
2006 Standout
Compound profiling for ABCC2 (MRP2) using a fluorescent microplate assay system
2007
MDR1 haplotypes significantly minimize intracellular uptake and transcellular P‐gp substrate transport in recombinant LLC‐PK1 cells
2006
FIP Guidelines for Dissolution Testing of Solid Oral Products
2018
Chemotherapy-induced resistance by ATP-binding cassette transporter genes
2007
The role of short-chain fatty acids in microbiota–gut–brain communication
2019 Standout
Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I
2010
Glycogen synthase kinase 3β inhibitors prevent hepatitis C virus release/assembly through perturbation of lipid metabolism
2017 StandoutNobel
Polymeric micelles for oral drug delivery
2010
Major Depressive Disorder
2008 Standout
P-glycoprotein and surfactants: Effect on intestinal talinolol absorption
2005
2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism
2012
Multidrug resistance 1 gene in inflammatory bowel disease: A meta-analysis
2006
Triiodothyronine Levels in Athyreotic Individuals During Levothyroxine Therapy
2008
Treatment of Clinical Hypothyroidism With Thyroxine and Triiodothyronine: A Literature Review and Metaanalysis
2007
Revised Estimates for the Number of Human and Bacteria Cells in the Body
2016 Standout
Natural compounds for cancer treatment and prevention
2009 Standout
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions
2021 Standout
Treatment of Hypothyroidism with Combinations of Levothyroxine plus Liothyronine
2005
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
2011 Standout
Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials
2007
Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs
2012
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Multifunctional quercetin conjugated chitosan nano-micelles with P-gp inhibition and permeation enhancement of anticancer drug
2018
Potential uses of T3 in the treatment of human disease
2005
Does Combination T4 And T3 Therapy Make Sense?
2012
Combined therapy with L-Thyroxine and L-Triiodothyronine compared to L-Thyroxine alone in the treatment of primary hypothyroidism
2010
Combined Treatment With Sertraline and Liothyronine in Major Depression
2007
Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers
2007
T4 plus T3 Treatment in Children with Hypothyroidism and Inappropriately Elevated Thyroid-Stimulating Hormone despite Euthyroidism on T4 Treatment
2010
Combined Therapy with Levothyroxine and Liothyronine in Two Ratios, Compared with Levothyroxine Monotherapy in Primary Hypothyroidism: a Double-Blind, Randomized, Controlled Clinical Trial
2005
Association of the Multidrug Resistance-1 Gene Single-Nucleotide Polymorphisms with the Tacrolimus Dose Requirements in Renal Transplant Recipients
2003
Resistance and intolerance to statins
2014
Effects of Either LT4 Monotherapy or LT4/LT3 Combined Therapy in Patients Totally Thyroidectomized for Thyroid Cancer
2007
Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum
2011 Standout
Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement
2014 Standout
2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum
2017 Standout
Pharmaceutical Cocrystals and Their Physicochemical Properties
2009 Standout
Fluorine in medicinal chemistry
2007 Standout
The Pharmacogenetics of Calcineurin Inhibitors: One Step Closer Toward Individualized Immunosuppression?
2005
Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2
2005
Dissemination and publication of research findings: an updated review of related biases
2010 Standout
Introduction to the human gut microbiota
2017 Standout
Drug Solubility: Importance and Enhancement Techniques
2012 Standout
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Thyroxine-Triiodothyronine Combination TherapyVersusThyroxine Monotherapy for Clinical Hypothyroidism: Meta-Analysis of Randomized Controlled Trials
2006
Thyroid Hormone Replacement for Central Hypothyroidism: A Randomized Controlled Trial Comparing Two Doses of Thyroxine (T4) with a Combination of T4 and Triiodothyronine
2007
Thyroid Hormone Regulation of Metabolism
2014 Standout
Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study
2018 StandoutNobel
Therapeutic Potential of Quercetin: New Insights and Perspectives for Human Health
2020 Standout
Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals
2011 Standout
Solubility Advantage of Pharmaceutical Cocrystals
2009 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients #
2009
Thyroid Hormone Replacement Therapy in Primary Hypothyroidism: A Randomized Trial Comparing l -Thyroxine plus Liothyronine with l -Thyroxine Alone
2005
Combination Treatment with T4 and T3: Toward Personalized Replacement Therapy in Hypothyroidism?
2012
The Controversial Role of Human Gut Lachnospiraceae
2020 Standout
Update on rifampin, rifabutin, and rifapentine drug interactions
2012
Microbial Contribution to the Human Metabolome: Implications for Health and Disease
2019
Thyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism
2009
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Treatment With Thyroid Hormone
2014
The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease
2020 Standout
Works of Thomas Gießmann being referenced
Simvastatin does not influence the intestinal P‐glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms
2006
CYP2D6genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects
2004
Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate–glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans
2006
Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans
2004
Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging
2005
The Talinolol Double-Peak Phenomenon Is Likely Caused by Presystemic Processing After Uptake from Gut Lumen
2005
Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14 : 1) is not superior to thyroxine alone to improve well‐being and cognitive performance in hypothyroidism
2004
Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir
2014
Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins
2006
The effects of the human MDR1 genotype on the expression of duodenal P‐glycoprotein and disposition of the probe drug talinolol
2002